key: cord-1007544-be49k54p
authors: Ando, Jun; Ngo, Minhtran C.; Ando, Miki; Leen, Ann; Rooney, Cliona M.
title: Identification of protective T-cell antigens for smallpox vaccines
date: 2020-05-08
journal: Cytotherapy
DOI: 10.1016/j.jcyt.2020.04.098
sha: 70c831d8e7e72fcc93db5ec5ff3608a594a801a9
doc_id: 1007544
cord_uid: be49k54p

Abstract E3L is an immediate-early protein of vaccinia virus that is detected within 0.5 hours of infection, potentially before the many immune evasion genes of vaccinia can exert their protective effects. E3L is highly conserved among orthopoxviruses and hence could provide important protective T-cell epitopes that should be retained in any subunit or attenuated vaccine. We have therefore evaluated the immunogenicity of E3L in healthy VV vaccinated donors. Peripheral blood mononuclear cells from healthy volunteers (n=13) who had previously received a smallpox vaccine (Dryvax®) were activated and expanded using overlapping E3L peptides and their function, specificity and anti-viral activity was analyzed. E3L-specific T-cells were expanded from 7 of 12 (58.3%) vaccinated healthy donors. 25% of these produced CD8+ T-cell responses and 87.5% produced CD4+ T-cells. We identified epitopes restricted by HLA-B35 and HLA-DR15. E3L-specific T-cells killed peptide-loaded target cells as well as vaccinia-infected cells but only CD8+ T-cells could prevent the spread of infectious virus in virus inhibition assays. The epitopes recognized by E3L-specific T-cells were shared with monkeypox and although there was a single amino acid change in the variola epitope homolog, it was recognized by vaccinia-specific T-cells. Therefore it might be important to include E3L in any deletion mutant or subunit vaccine and E3L could provide a useful antigen to monitor protective immunity in humans.

Although smallpox (variola) has been eradicated by vaccination programs that ceased in the 1980s [1, 2] , stocks of variola still exist and its potential as a biological weapon has become an international concern warranting the continued availability of a smallpox vaccine [3] [4] [5] . Outbreaks of animal poxviruses, particularly monkeypox [6, 7] , in human populations further highlight the continued need for a vaccine, and sequence homology between vaccinia virus (VV), variola, and monkeypox, all members of the orthopoxvirus genus means that VV is an effective vaccine for all [8] .

While the current NYCBH strain of VV (Dryvax ® ) [9] , is highly effective, it is a live, nonattenuated virus and contraindicated in young children and the elderly as well as in individuals who are immunosuppressed, are pregnant or have skin or heart conditions; altogether about 25% of the population [10] . Hence, there is significant interest in a less pathogenic, but equally immunogenic vaccine. The highly attenuated modified vaccinia Ankara (MVA) has proved safe in HIV-infected persons and is a promising alternative vaccine [11] . However, having lost up to 15% of its genome after extensive passage in chicken embryo fibroblasts [12, 13] , it cannot replicate in human cells and therefore requires doses over 100 fold higher than for Dryvax ® and booster vaccination to provide equivalent protection in animal models [14, 15] .

E3L is an immediate early protein that inhibits the innate immune response to viral double stranded RNA [16] . An E3L deletion mutant provided a promising attenuated vaccine that was safe and effective in murine and rabbit infection models, but it did not prevent lethal infections in a monkeypox model [17] . Since E3L is expressed within 0.5 hours of infection by VV [18] , it should be processed and presented to the cellular immune responses before immune evasion genes of VV are expressed and allow T cell killing before newly replicated virus is released from infected cells. If so, this may explain the lack of efficacy of E3L deletion mutant vaccines. Hence, E3L and other immediate early genes, might provide important, protective T-cell epitopes that should be preserved in any live-attenuated or subunit vaccine. The identification of viral proteins that induce protective T-cells and are recognized by a majority of immune humans would be useful for the development of subunit or deletion mutant vaccines, might determine the relative importance of each arm of the immune response and assist in the monitoring and evaluation of effective T-cell responses to vaccination.

We therefore asked whether E3L contained immunodominant epitopes for T-cells and evaluated the ability of E3L-specific T-cells to kill VV-infected cells and prevent infectious virus spread in a tissue culture model. E3L-specific CD8+ T-cells could recognize and kill VV infected cells before they were able to replicate new virus. Hence, it might be important to retain E3L in any deletion mutant or subunit vaccine and E3L would provide a useful antigen to monitor protective immunity in humans.

Donors and cell lines. Peripheral blood mononuclear cells (PBMCs) were obtained with informed consent on Baylor College of Medicine Institutional Review Boardapproved protocols, from healthy volunteers who had previously received the VV vaccine, Dryvax ® . PBMCs were used to generate VV antigen-specific T-cells (VVSTs) as well as dendritic cells (DCs) and activated T-cells (ATCs) for use as antigenpresenting cells (APCs).

Activated T-cells (ATCs) for use as autologous target cells were generated by stimulation of PBMCs (5x10 5 cells per well) in 24-well non-tissue culture treated plates coated with a CD3 antibody produced by the OKT3 hybridoma (ATCC #CRL 8001, Manassas, VA) and CD28 antibody (Becton Dickinson BD, Franklin Lakes, NJ) (each at 1 μg/ml) (CD3/28 MAbs). ATCs were maintained in T-cell medium (RPMI 1640, (Hyclone, Waltham, MA) supplemented with 45% Click's medium (Irvine Scientific, Santa Ana, CA), 2 mmol/l GlutaMAX TM-I (Invitrogen, Carlsbad, CA), and 5% Human AB Serum (Valley Biomedical, Winchester, VA) and supplemented with IL-2 (50U/ml) (R&D Systems, Minneapolis, MN), which was replenished every 3 to 4 days. Two days before antigen-specific T-cell restimulation ATCs were reactivated on CD3/28 MAbcoated plates to upregulate costimulatory molecules [19] . and GM-CSF (R&D systems) were replenished on day 3. On day 5, DCs were matured in DC medium using a cytokine cocktail containing 100 ng/ml IL-6 (R&D systems), 10 ng/ml IL-1β (R&D systems), 10 ng/ml TNF-α (R&D systems), 1 μg/ml PGE2 (Sigma-Aldrich, St. Louis, MO), 800 U/ml GM-CSF and 1,000 U/ml IL-4 for 48 hours [20, 21] .

Loading DCs or ATCs with pepmixes. Mature DCs or ATCs were pelleted and pulsed with pepmixes spanning E3L or other VV antigens for 30 minutes at 37C in 5% CO 2 . Pepmix sequences were derived from the Western Reserve strain of vaccinia.

The E3L pepmix (Genemed Synthesis, San Antonio, TX) is an overlapping peptide library consisting of thirty five 20-mer peptides overlapping by 15 amino acids covering the complete sequence of E3L. These peptides were aliquoted into 12 pools containing 5 to 6 peptides per pool such that each peptide was uniquely present in two pools ( Fig.   2B ) [22] . Pepmixes spanning A10L, H3L, C7L, G5R and B22R were obtained off the shelf from JPT technologies (Berlin, Germany). 

determine the cytotoxicity activity and virus inhibition assay were Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (LCLs) derived from PBMC using EBV isolate B95-8 in the presence of cyclosporin A as previously described [25] [26] [27] . A recombinant kinase deletion mutant (TK-VV) derived from the Western Reserve strain was used at a multiplicity of infection (MOI) of 1 for the infection of LCLs. LCL pellets were incubated with virus for 1 hour, washed 3 times, diluted to 1 × 10 6 cells/ml and incubated at 37℃, 5% CO 2 . As cytotoxicity assay targets we used LCLs that had been infected with VV for 2, 4 and 8 hours, respectively.

autologous VVSTs for 48 hours at 37℃ in 5% CO 2 . To measure T-cell inhibition of virus replication in the LCLs, the cocultures were harvested and lysed by three freeze-thaw cycles and stored at -80℃. We then added 10-fold dilutions of cell lysate (from 10 -1 to 10 -7 ) to confluent MRC-5 fibroblasts (ATCC, Manassas, VA) for 1 hour at 37℃, then added fresh medium. Cells were incubated at 37℃, 5% CO 2 for 24 hours. Virus plaques were quantified after washing wells with PBS and adding 0.5ml of crystal violet (Sigma-Aldrich, St. Louis, MO) solution to each well for 5 min, followed by washing with PBS. Plaques were counted and virus titer estimated. 

To identify CD8+ T-cell epitopes in E3L, CD8+ T-cells were stimulated on days 0 and 9 with E3L pepmix-pulsed DCs in the presence of IL-4 and IL-7. On day 16, they were challenged with peptide pools of 5 to 6 E3L peptides, in which each peptide was uniquely represented just two pools (Fig.   2B ) [22] . Donor 1 responded to pools 4 and 10 ( Fig. 2A) , indicating specificity for peptide 22 that is common to both pools (Fig. 2C) . To validate the response to peptide peptide-pulsed ATCs, 57.5% for HLA-B35, 5% for HLA A24, 16% for A26 and 29% for B40) (Fig. 2E) . Specific killing was blocked by HLA class I MAbs (32.1% and 37.5% specific lysis) (Fig. 2F) . We fine mapped the E3L epitope within peptide 22, by testing every possible 9mer for its ability to mediate recognition of HLA-B35 positive target cells. Using T-cells from HLA B35 positive donors 1 and 2, we identified a novel VV epitope aa 117-125 -NPVTVINEY (NPV) (Fig. 2G) . We then generated an HLA B35-NPV tetramer that recognized 18.1% and 1.9% of CD8+ VZV-specific T-cells from donors 1 and 2. 3A ) that contained peptides 31 and 32 in common (Fig. 3B) . We validated the response to peptides 31 and 32 individually, and the HLA class II restriction by demonstrating a decreased response in the presence of HLA-DR MAbs (Fig. 3C) . Three other donors (donors 4, 5 and 6) also responded to peptides 31 and 32 and were also inhibited by HLA-DR MAb (Fig. 3D) . All peptide 31/32-responsive donors shared HLA-DR15. The minimal E3L epitope in peptides 31 and 32, identified a new VV epitope aa156-170-GRVFDKADGKSKRDA (GRV) (Fig. 3E) . CD4+ T-cells from HLA-DR15 negative donors, did not respond to peptides 31 and 32 (data not shown).

The HLA-A, -B, -DRB1 and -DQB1 alleles of all donors screened is shown in Table 1 .

In summary, CD8 VVSTs were induced from PBMC of donors 1 and 2. We found a VV epitope aa 117-125-NPV in these CD8 VVSTs as we have shown in Figure 2 . By contrast, CD4 VVSTs were induced from donors 2 to 8. As we showed in Figure 3 

We predicted that E3L-specific T-cells would be among the most rapid killers of newly infected cells, since E3L is not only expressed early after infection (transcript detected within 30 minutes), but is also packaged into the virion [28] , specific lysis, respectively) (Fig. 5A) . To determine if CD8+ E3L-specific T-cells could inhibit virus replication, they were added to autologous LCLs two hours after infection with VV at a T-cell to LCL ratio of 5:1 and cultured for 2 days. Coculture lysates were then added to MRC-5 fibroblasts at limiting dilution to measure the amount of virus produced by the infected LCLs using a plaque assay. Figure 5B shows that E3Lspecific CD8+ T-cells from both donors could reduce the titer of VV harvested from LCLs by 5 logs from 10 7 pfu/ml to 10 2 pfu/ml.

To determine if T-cells specific for other vaccinia proteins were able to prevent the spread of VV within infected cell cocultures, we stimulated CD4+ and CD8+ T-cells from donors 2, 4 and 5 with DCs loaded with vaccinia pepmixes from G5R (early/core), C7L (early) and B22R (early), A10L

(late/virion) and H3L (late/membrane) that were available off the shelf from JPT Peptide Technologies GmbH (Berlin, Germany) ( A10L, C7L and E3L-specific CD8 CTLs killed both pepmix-pulsed LCLs and VV infected LCLs. However, only E3L-specific T-cells prevented VV replication in co-culture virus inhibition assay (Fig. 6A ). B22R-specific CD8+ T-cells from donor 4 neither killed VV infected target LCLs nor prevented VV replication (Fig. 6B ). E3L and C7L-specific CD8+ T-cells both killed VV infected LCLs, whether cocultured at 2, 4 or 8 hours after infection with VV. A10L-specific CD8+ T-cells killed VV infected LCL 8 hrs after infection, but not if cocultured 2 and 4 hrs after infection with VV, despite its presence in the virion [28] , but perhaps reflecting its late gene expression (Fig. 6C) .

CD4+ T-cells specific for A10L-, H3L-, G5R-and E3L did not killed VV infected target cells, nor could they prevent VV replication in cocultures ( Fig. 6D and 6E ). Table 2 shows the function, time of transcription of each VV gene and presence in virion as well as comparison of vaccinia proteins using cytotoxicity and virus inhibition assay in this study. Hence the only T-cells that were able to prevent infectious virus spread were CD8+ E3L-specific T-cells. The failure of CD4-E3L-specific T-cells was likely because killing by CD4+ T-cells is slower than that of CD8+ T-cells [36] .

We have demonstrated that the immediate early E3L protein of VV provides T-cell epitopes that can be recognized in the context of HLA B35 and HLA DR15. E3L is highly conserved among poxviruses, but although the CD8 epitope we identified in VV is shared with monkeypox, there is a single amino acid change in the variola epitope (NPVTIINEY) that contains a V to I mutation in position 5. However, position 5 is a nonanchor position and VV E3L-NPVTVINEY-specific T-cells recognized the variola epitope and should therefore provide protection not only against VV, but also variola and monkeypox. E3L-specific T-cells could kill peptide-loaded target cells as well as VVinfected cells and could prevent the spread of infectious virus in a cell culture system. By contrast, although CD8+ T-cells specific for an early VV protein, C7L and a late/virion protein A10L were able to kill vaccinia-infected cells, they were unable to prevent VV amplification and infectious virus spread. CD4+ T-cells specific for E3L, H3L, G5R and A10L were detected, but were unable to kill infected target cells nor prevent infectious virus spread in our assays ( Table 2 ). This suggests that simple induction of a T-cell immune response to a viral antigen by vaccination may not guarantee that the vaccine will be effective. presented by infected cell before the expression of the many immune evasion genes encoded by poxviruses, they may never be presented on infected cells and will have little biological relevance [37] [38] [39] [40] . In our assay, CD8+ T-cells specific for C7L and A10L, expressed early and late respectively were able to kill virus-infected LCLs, but while Tcells specific for B22R, expressed early, were able to kill pepmix-pulsed LCLs, they could not kill VV-infected LCLs. B22R may not be expressed early enough in the viral replicative cycle to escape viral inhibition of antigen processing, while recognition of the late protein, A10L may be explained by its abundant presence in the virion. Thus A10L core antigens enter the cell at the time of infection and will be among the first proteins processed and presented to the immune response.

CD4+ T-cells, whether specific for E3L, H3L, G5R or A10L, did not kill VV-infected LCLs, regardless of the timing of their expression. This may be because these T-cells lacked cytolytic activity, because the frequency of CD4+ T-cells was too low or because viral antigens were not presented by infected cells on HLA class II. Indeed Li et al., showed that the window of opportunity for CD4+ T-cell recognition of VV-infected cells diminished from one hour after infection, and Rehm et al., suggested that this resulted from decreased loading of peptides into the MHC II cleft [40] [41] [42] .

Even if VV-infected cells are killed by VV-specific CD8+ T-cells, their antiviral activity depends on their ability to prevent the release of infectious virus. VV has a rapid replication cycle, and new virus particles can be produced in some cell types within 4 hours of infection. Therefore killing of newly infected cells must occur rapidly to prevent virus replication and spread. E3L-specific CD8+ T-cells were able to prevent virus replication in infected cells, only if added within 2 hours of infection, while CD8+ T-cells specific for the early protein, C7L, that is not expressed until 2 hours post infection [18] were unable to prevent infectious spread despite their ability to kill infected target cells.

These observations suggest that rapid killing is required for virus control and indicates the importance of T-cells specific for rapidly presented proteins. Our "inhibition of virus spread" assay can therefore test for protective T-cells, and may be helpful for the screening of potential VV vaccines prior to testing in long, complex and expensive studies in animals. It will be important to test other IE antigens as well as abundant virion proteins for their abilities to activate protective T-cells, since in our small study of 13 donors, CD8 responses to E3L appeared restricted to HLA B35 donors.

Although IFN- alone is able to inhibit the replication of VV in murine fibroblasts, it has no such effect on human fibroblasts due to the effect of several vaccinia immune evasion genes including E3L [43] , therefore local production of IFN-by T-cells specific for viral proteins cross presented on APCs would not be expected to control virus spread. This emphasizes the importance of protective T-cells [44] .

T cell recognition of VV antigens is broad and Sette et al. [45] , reported T-cell recognition of 250 epitopes in 23 VV antigens. As a result of these studies the NIAID compiled a bank of potential HLA class I-restricted VV epitopes that were identified using the SYTHPETHI and Bioinformatics and Molecular Analysis Section of the National Institutes of Health BIMAS (www-bimas.cit.nih.gov) algorithms [46] . However, in our hands, when tested in VV-immune individuals with appropriate HLA alleles, only one of these epitopes elicited a T-cell response (not shown). We therefore took a different approach to the identification of protective epitopes and hypothesized that the viral proteins first presented to the immune system after infection were most likely to induce protective T-cells. These antigens would include virion proteins carried into the infected cell during infection as well as immediate early proteins expressed rapidly after infection. Of immediate early proteins, the most abundant are likely to be most immunogenic. E3L is abundantly detected within 0.5 hours of infection, potentially before the many immune evasion genes of VV take their effect and is also carried in the virion so that it can exert its immune evasion functions promptly. E3L inhibits innate immunity to poxvirus infection by inhibiting interferon responses to dsRNA and downstream activation of MAP kinase and NFB pathways [16, 47, 48] . We predicted that because of its abundance and rapid expression, E3L would induce T-cells that could protect against virus infection. Indeed CD8+ E3L-specific T-cells were able to kill newly infected cells and prevent infectious VV spread in autologous LCLs. respectively. There are other potential epitopes within E3L with higher (better) scores, restricted by other HLA alleles. However, these epitopes were not detected by our Tcells even though our donor panel carried the predicted HLA alleles.

VVs deleted for E3L showed early promise as vaccines and induced Th1 responses to VV that protected against lethal challenge with wildtype virus in mice and rabbits [17, 49, 50] . However, the same vaccine evaluated in cynomolgus macaques, provided only partial protection against monkeypox compared to wildtype virus [17] . If the E3L protein protective T-cells are to be produced. In this virus the first proteins to be expressed immediately after virus entry, are the polyproteins pp1a and pp1b, whereas the SPIKE protein, which is the target of neutralizing antibodies as well as most vaccines, is not expressed until much later, after the negative strand is produced, transcribed and translated.

VV is also used as a vector for heterologous vaccine antigens and immediate early expression of vaccine antigens is likely to be important for optimal transgene expression and direct induction of a CD8+ immune response by infected cells [51, 52] . Deletion of E3L in VV vaccine vectors may prolong the persistence of VV by removing important Tcell epitopes and prolonging the vaccine effect. However, since E3L deletion from wildtype VV may increase pathogenicity, this strategy should be tested in an attenuated strains, such as MVA [53] . Table 1 Listing of CD8 and CD4 T cell peptides in E3L. Table 2 Comparison each of vaccinia proteins in this study.

Vaccinia virus vaccines: past, present and future

A successful eradication campaign. Global eradication of smallpox

Being prepared: bioterrorism and mass prophylaxis: part II

The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks

Modeling potential responses to smallpox as a bioterrorist weapon

Phylogenetic and ecologic perspectives of a monkeypox outbreak

Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus

Developing new smallpox vaccines

US Civilian Smallpox Preparedness and Response Program

Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase

Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques

Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes

Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)

Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions

Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma

Analysis of CD8 T cell reactivity to cytomegalovirus using proteinspanning pools of overlapping pentadecapeptides

Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant

Complementation of Antigen-presenting Cells to Generate T Lymphocytes With Broad Target Specificity

Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines

Comparison of the yield of infectious virus from clones of human and simian lymphoblastoid lines transformed by Epstein-Barr virus

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease

Protein composition of the vaccinia virus mature virion

Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I-restricted cytotoxic T lymphocytes

Vaccinia virus mutants with alanine substitutions in the conserved G5R gene fail to initiate morphogenesis at the nonpermissive temperature

Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons

Vaccinia virus host range genes

The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles

Vaccinia virus structural polypeptide derived from a high-molecular-weight precursor: formation and integration into virus particles

Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo

High efficiency of antiviral CD4(+) killer T cells

The interferon system and vaccinia virus evasion mechanisms

Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen

Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression

Disruption of MHC class IIrestricted antigen presentation by vaccinia virus

Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II

Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II

Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo

Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts

Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens

HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation

Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways

Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme

The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus

Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination

The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus

Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses

) Fine mapping of E3L 9-mer peptide within peptide 22 (20-mer). E3L-specific CD8+ T-cells from donor 1 and donor 2 (HLA-B35 donors) were stimulated with individual 9-mer peptides and IFNγ production measured

Identification of CD4+ T-cell epitopes within E3L from HLA-DR15 donors. (A) II DR. (D) E3L-specific CD4+ T-cells from donors 3 to 6 (HLA-DR15 donors) were stimulated with peptides 31 and 32, with or without HLA class II DR, DP and DQ blocking donors 1 and 2 were stained with the variola variant tetramer -HLA-B35/NPV V→I (and anti-CD8 antibody and analyzed by FACS

Vaccinia-specific T-cells can kill VV-infected LCL and prevent VV replication

E3L-specific CD8+ T-cells from donors 1 and 2 were cultured with autologous or HLA-B35 matched allogeneic LCLs at 2, 4 and 8 hours after infection with VV. Specific lysis was evaluated in 6 hour Cr 51 release assay at E:T ratio of 40:1, 20:1, 10:1 and 5:1 . (B) VV-infected LCLs were cultured alone or with E3L-specific CD8+ T-cells at a T-cells : VV-infected LCL ratio of 5:1, or with stock VV or medium alone